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ess: ulla.hodgson@hus.Summary Idiopathic pulmonary fibrosis is the most common of the idiopathic
interstitial lung diseases referring to the histo-pathological entity of usual
interstitial pneumonia. It has been hypothesized that inflammation may trigger
the multiformic fibrotic lesions found in the affected lung, and defects in the innate
immune defense, including the complement, can predispose to pulmonary fibrosis.
The polymorphism C5507G in the Complement Receptor 1 gene has been recently
associated with idiopathic pulmonary fibrosis. C5507G causes an amino acid change
from proline to arginine, and opens a potential cleavage site for trypsin-like enzymes
and, therefore, a potential mechanism for increased shedding of the molecule from
the cell surface. We studied the polymorphism in 96 Finnish patients with idiopathic
pulmonary fibrosis and 164 population based controls. All the patients and controls
were C5507 homozygous suggesting that either the Finns do not carry the G5507
polymorphism or it is extremely rare. We conclude that G5507 is not a susceptibility
allele for idiopathic pulmonary fibrosis among Finnish patients.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Complement Receptor 1 (CR1) is located on the
chromosome 1q32. The gene encodes a single-chainElsevier Ltd. All rights reserv
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fi (U. Hodgson).cell surface membrane glycoprotein, named CD35
(complement component 3b/4b receptor, C3-bind-
ing protein). CD35 is mainly expressed on the
surface of peripheral blood cells, especially on
erythrocytes (http://www.ncbi.nlm.nih.gov/
prow). CD35 binds to circulating antigen–antibody
complexes in the presence of the complement
components C3b and C4b. By the action of ery-
throcytes, immune complexes are then transferreded.
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Immune complexes that escape the reticuloen-
dothelial system can in turn increase the kind of
tissue damage associated with many immune
diseases.
A total of 11 amino acid changing polymorphisms
of the coding sequence of CR1 have been reported
(http://www.ncbi.nlm.nih.gov/SNP). The substitu-
tion of C to G in exon 33 (rs3811381) causes an
amino acid change from proline to arginine, named
Pro1827Arg. The polymorphism opens a potential
cleavage site for trypsin-like proteases that can
increase shedding of the receptor expressed on the
cell surface and, in return, decrease the activity of
the complement.3 C5507G has been associated
previously with idiopathic pulmonary fibrosis (IPF)
among Italian patients.4 G5507 homozygosity was
significantly more common in patients with IPF than
in control subjects or COPD patients. In this study
we report the results among the Finnish IPF
patients and population-based controls.Methods
Patients
The study population consists of 96 Finnish IPF
patients (42 males and 54 females). Thirty-six of
the patients were recruited at the Pulmonary Clinic
of the Helsinki University Hospital, 30 at the
Southern and Eastern Savo Central Hospitals, and
30 at the other Pulmonary Clinics in Finland. The
diagnosis was made according to the ATS/ERS
diagnostic criteria.5,6 At the time of diagnosis,
the age of the patients was on average 62 yrs
(ranging from 26 to 83 yr), patients’ lung vital
capacity was 74% (ranging from 35% to 102%), and
diffusing capacity for carbon monoxide 58% (ran-
ging from 28% to 91%) of predicted.
The control population consisted of 96 voluntary
blood donors across Finland and 68 regional health
controls from the Savo region.7
Genotyping and sequencing
DNA was extracted from peripheral blood leuco-
cytes. We amplified the regions of genomic DNA
comprising the C5507G polymorphism using two
primer pairs: (A) 50CTTTTGTCCAAATCCTCCAG and
30AAAGTTAAGCTCACAAACAAATACCA; and (B) 50TT-
CAACCTCATTGGGGAGAG and 30GGCAGGGCTGCT-
CCAAA. The polymorphism was studied using two
restriction enzymes HpyCH4III (amplicon A) and
MnlI (amplicon B) (New England Bio Labs, MA). Thelength of the PCR product A (HpyCH4III specific
cleavage site) for the major allele (C5507) was
328 bp, and in the presence of the minor allele
(G5507) 164 bp+164 bp. The lengths of the PCR
product B (MnlI specific cleavage site) for the major
allele (C5507) were 37+29+9 bp, and in the pre-
sence of the minor allele (G5507) 66+9 bp.
Sequencing of the genomic DNA was done on the
96-capillary automated sequencer (ABI3730 Auto-
matic DNA sequencer, Applied Biosystems).Results
We studied C5507G among a total of 96 IPF patients
and 164 controls. One third of the patients
originated from a regional enrichment of familial
IPF in South eastern Finland.6 The rest of the
patients represented the sporadic IPF cases across
Finland. The diagnostic criteria and clinical out-
come of the disease were verified from the
patients’ medical records. For 17 patients expres-
sing atypical clinical features of IPF, such as early
onset of the disease, the surgical biopsy with the
UIP pattern further confirmed the diagnosis.
For genotyping we used two restriction enzymes
showing altered restriction sites for the studied
polymorphism. First, when HpyCH4III was used,
none of the PCR fragments were digested, suggest-
ing that all the study subjects were C5507 homo-
zygous. In the absence of positive controls, we
chose to confirm the genotyping results with
another restriction enzyme, MnlI. Consistent with
the previous results, again, only the major allele
(C5507) was recognized. Since the results were
somewhat unexpected, we then verified by sequen-
cing that all the patient were C5507 homozygous.Discussion
Results based on 520 studied chromosomes strongly
suggest that the Finns do not carry the G5507 allele
at all or it is extremely rare. Not finding the G5507
polymorphism was to some extent surprising, since
previous studies among other Caucasian popula-
tions have estimated the frequency of the carrier-
ship of G5507 at around 20%.4,8 Single allele
frequencies, however, are known to vary in several
standard deviations among European populations.9
The Finns have lived in isolation and reminded a
small population for centuries, which also increases
the possibility of losing some alleles simply because
of random drift.10 Random drift has the strongest
effect on rare alleles (frequencyo5%), as it has
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the DF508 mutation in cystic fibrosis, but the loss of
a common allele seldom occurs.10 Our study group
included a genetically isolated subgroup of IPF
patients with strong familial background and likely
related to each other within a couple of genera-
tions. This, however, does not explain our findings,
since polymorphism was found neither among
sporadic IPF patients nor controls representing
the Finns across the country.
Recent epidemiological studies in Finland show
that IPF is not less common in Finland than in other
European populations. Based on international diag-
nostic criteria, prevalence of IPF in Finland, 16–18
per 100 000, is concordant with reports from other
populations.6,11,12,13,14 According to present knowl-
edge, the clinical entities of IPF do not differ
among populations. The absence of G5507 poly-
morphism allows us to assume that molecular
genetic mechanisms other than C5507G explain
the etiology to IPF among the Finnish patients.Acknowledgements
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